Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Approved For Marketing No phase listed Expanded access

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT00338247

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00338247. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies

Study identification

NCT ID
NCT00338247
Recruitment status
Approved For Marketing
Study type
Expanded access
Phase
Not listed
Lead sponsor
Novartis
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2006 (Type not available)
Primary completion
Mar 2015 (Actual)
Completion
Mar 2015 (Actual)
Last update posted
Apr 6, 2016

2006 – 2015

United States locations

U.S. sites
159
U.S. states
43
U.S. cities
138
Facility City State ZIP Site status
Novartis Investigative Site Huntsville Alabama 35805 —
Novartis Investigative Site Anchorage Alaska 99508 —
Novartis Investigative Site Glendale Arizona 85304 —
Novartis Investigative Site Fayetteville Arkansas 72703 —
Novartis Investigative Site Little Rock Arkansas 72205 —
Novartis Investigative Site Bellflower California 90706 —
Novartis Investigative Site Burbank California 91505-4866 —
Novartis Investigative Site Gilroy California 95020 —
Novartis Investigative Site Long Beach California 90806 —
Novartis Investigative Site Long Beach California 90813 —
Novartis Investigative Site Newport Beach California 92663 —
Novartis Investigative Site San Diego California 92123 —
Novartis Investigative Site San Francisco California 94115-1710 —
Novartis Investigative Site Santa Rosa California 95403-1757 —
Novartis Investigative Site Stockton California 95204 —
Novartis Investigative Site Aurora Colorado 80010 —
Novartis Investigative Site Boulder Colorado 80304 —
Novartis Investigative Site Lafayette Colorado 80026 —
Novartis Investigative Site Hartford Connecticut 06105 —
Novartis Investigative Site Manchester Connecticut 06040 —
Novartis Investigative Site New Havey Connecticut 06511 —
Novartis Investigative Site Norwich Connecticut 06360 —
Novartis Investigative Site Washington D.C. District of Columbia 20007 —
Novartis Investigative Site Fort Lauderdale Florida 33328 —
Novartis Investigative Site Fort Myers Florida 33916 —
Novartis Investigative Site Fort Walton Beach Florida 32547 —
Novartis Investigative Site Gainesville Florida 32605 —
Novartis Investigative Site Hollywood Florida 33021 —
Novartis Investigative Site Jacksonville Florida 32256 —
Novartis Investigative Site Miami Florida 33133 —
Novartis Investigative Site Orlando Florida 32804 —
Novartis Investigative Site Orlando Florida 32806 —
Novartis Investigative Site Tampa Florida 33607 —
Novartis Investigative Site Augusta Georgia 30901 —
Novartis Investigative Site Brunswick Georgia 31525 —
Novartis Investigative Site Macon Georgia 31201 —
Novartis Investigative Site Marietta Georgia 30060 —
Novartis Investigative Site Tucker Georgia 30084 —
Novartis Investigative Site Honolulu Hawaii 96813 —
Novartis Investigative Site Boise Idaho 83712 —
Novartis Investigative Site Chicago Illinois 60637 —
Novartis Investigative Site Decatur Illinois 62526 —
Novartis Investigative Site Galesburg Illinois 61401 —
Novartis Investigative Site Highland Park Illinois 60035 —
Novartis Investigative Site Joliet Illinois 60435 —
Novartis Investigative Site Peoria Illinois 61615 —
Novartis Investigative Site Zion Illinois 60099 —
Novartis Investigative Site Indianapolis Indiana 46202 —
Novartis Investigative Site Bettendorf Iowa 52722 —
Novartis Investigative Site Cedar Rapids Iowa 52403 —
Novartis Investigative Site Council Bluffs Iowa 51503 —
Novartis Investigative Site Sioux City Iowa 51101-1733 —
Novartis Investigative Site Waterloo Iowa 50702 —
Novartis Investigative Site Baton Rouge Louisiana 70809 —
Novartis Investigative Site Metairie Louisiana 70006 —
Novartis Investigative Site Portland Maine 04101 —
Novartis Investigative Site Scarborough Maine 04074 —
Novartis Investigative Site Waterville Maine 04901 —
Novartis Investigative Site Baltimore Maryland 21231-1000 —
Novartis Investigative Site Baltimore Maryland 21237 —
Novartis Investigative Site Chevy Chase Maryland 20815 —
Novartis Investigative Site Frederick Maryland 21701 —
Novartis Investigative Site Boston Massachusetts 02111 —
Novartis Investigative Site Boston Massachusetts 02118 —
Novartis Investigative Site Fall River Massachusetts 02721 —
Novartis Investigative Site Peabody Massachusetts 01960 —
Novartis Investigative Site Ann Arbor Michigan 48106 —
Novartis Investigative Site Detroit Michigan 48202 —
Novartis Investigative Site Royal Oak Michigan 48073 —
Novartis Investigative Site Troy Michigan 48085 —
Novartis Investigative Site Duluth Minnesota 55802 —
Novartis Investigative Site Jackson Mississippi 39202 —
Novartis Investigative Site Columbia Missouri 65201 —
Novartis Investigative Site Kalamazoo Missouri 49007 —
Novartis Investigative Site Kansas City Missouri 64118 —
Novartis Investigative Site Springfield Missouri 65807 —
Novartis Investigative Site St Louis Missouri 63110 —
Novartis Investigative Site St Louis Missouri 63141 —
Novartis Investigative Site Billings Montana 59101 —
Novartis Investigative Site Great Falls Montana 59405 —
Novartis Investigative Site Grand Island Nebraska 68803 —
Novartis Investigative Site Lincoln Nebraska 68510 —
Novartis Investigative Site North Platte Nebraska 69103 —
Novartis Investigative Site Omaha Nebraska 68114 —
Novartis Investigative Site Omaha Nebraska 68124-2346 —
Novartis Investigative Site Las Vegas Nevada 89102 —
Novartis Investigative Site Exeter New Hampshire 03833 —
Novartis Investigative Site Flemington New Jersey 08822 —
Novartis Investigative Site Freehold New Jersey 07728 —
Novartis Investigative Site Little Silver New Jersey 07739 —
Novartis Investigative Site Livingston New Jersey 07039 —
Novartis Investigative Site Mountain Lakes New Jersey 07046 —
Novartis Investigative Site Newark New Jersey 07112 —
Novartis Investigative Site Buffalo New York 14221 —
Novartis Investigative Site Buffalo New York 14263 —
Novartis Investigative Site East Setauket New York 11733 —
Novartis Investigative Site East Syracuse New York 13057 —
Novartis Investigative Site Fresh Meadows New York 11366 —
Novartis Investigative Site Glens Falls New York 12801 —
Novartis Investigative Site New York New York 10003 —
Novartis Investigative Site New York New York 10011 —
Novartis Investigative Site New York New York 10016 —
Novartis Investigative Site New York New York 10065 —
Novartis Investigative Site Asheville North Carolina 28816 —
Novartis Investigative Site Charlotte North Carolina 28203 —
Novartis Investigative Site Charlotte North Carolina 28204 —
Novartis Investigative Site Fayetteville North Carolina 28304 —
Novartis Investigative Site Greensboro North Carolina 27403 —
Novartis Investigative Site Bismarck North Dakota 58501 —
Novartis Investigative Site Fargo North Dakota 58122 —
Novartis Investigative Site Cincinnati Ohio 45219 —
Novartis Investigative Site Cincinnati Ohio 45242 —
Novartis Investigative Site Cleveland Ohio 44106 —
Novartis Investigative Site Columbus Ohio 39705 —
Novartis Investigative Site Columbus Ohio 43210 —
Novartis Investigative Site Sandusky Ohio 44870 —
Novartis Investigative Site Oklahoma City Oklahoma 73109 —
Novartis Investigative Site Tulsa Oklahoma 74104 —
Novartis Investigative Site Tulsa Oklahoma 74133 —
Novartis Investigative Site Klamath Falls Oregon 97601 —
Novartis Investigative Site Portland Oregon 97213 —
Novartis Investigative Site Drexel Hill Pennsylvania 19026 —
Novartis Investigative Site Philadelphia Pennsylvania 19104 —
Novartis Investigative Site Philadelphia Pennsylvania 19106 —
Novartis Investigative Site Philadelphia Pennsylvania 19111 —
Novartis Investigative Site Pittsburgh Pennsylvania 15212-4772 —
Novartis Investigative Site Pittsburgh Pennsylvania 15213 —
Novartis Investigative Site Pottstown Pennsylvania 19464 —
Novartis Investigative Site Sayre Pennsylvania 18840 —
Novartis Investigative Site State College Pennsylvania 16803 —
Novartis Investigative Site Charleston South Carolina 29403 —
Novartis Investigative Site Columbia South Carolina 29210 —
Novartis Investigative Site Florence South Carolina 29506 —
Novartis Investigative Site Mt. Pleasant South Carolina 29464 —
Novartis Investigative Site Knoxville Tennessee 37916 —
Novartis Investigative Site Memphis Tennessee 38120 —
Novartis Investigative Site Nashville Tennessee 37203 —
Novartis Investigative Site Arlington Texas 76012 —
Novartis Investigative Site Austin Texas 78731 —
Novartis Investigative Site Austin Texas 78759 —
Novartis Investigative Site Dallas Texas 75230 —
Novartis Investigative Site Dallas Texas 75246 —
Novartis Investigative Site El Paso Texas 79912 —
Novartis Investigative Site Houston Texas 77030 —
Novartis Investigative Site Houston Texas 77230-1439 —
Novartis Investigative Site San Antonio Texas 78207 —
Novartis Investigative Site Salt Lake City Utah 84112-5550 —
Novartis Investigative Site Fairfax Virginia 22031 —
Novartis Investigative Site Richmond Virginia 23230 —
Novartis Investigative Site Richmond Virginia 23294 —
Novartis Investigative Site Kennewick Washington 99336 —
Novartis Investigative Site Mount Vernon Washington 98273 —
Novartis Investigative Site Seattle Washington 98112 —
Novartis Investigative Site Tacoma Washington 98405 —
Novartis Investigative Site Walla Walla Washington 99362 —
Novartis Investigative Site Morgantown West Virginia 26506 —
Novartis Investigative Site Green Bay Wisconsin 54311 —
Novartis Investigative Site La Crosse Wisconsin 54601 —
Novartis Investigative Site Marshfield Wisconsin 54449 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 294 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00338247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 6, 2016 · Synced Nov 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.